| DC21452 |
Artefenomel |
Artefenomel (OZ439) is a novel, next-generation antimalarial ozonide that demonstrates high potentcy against P. falciparum in vitro and P. berghei in vivo (K1/NF54, IC50=2.0/3.2 nM).. |
|
| DC21451 |
Arterolane |
Arterolane (OZ277. |
|
| DC12024 |
ARV-825
Featured
|
ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively. |
|
| DC12614 |
Arylsulfonamide 64B |
Arylsulfonamide 64B (HIF inhibitor 64B) is a small molecule HIF pathway inhibitor, blocks hypoxia-induced expression of c-Met and CXCR4 and uveal melanoma (UM) cell migration. |
|
| DC20687 |
AS 2553627 |
AS 2553627 (AS2553627) is a novel potent, selective pan-JAK inhibitor with IC50 of 0.46, 0.30, 0.14 and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. |
|
| DC8256 |
AS 602801(Bentamapimod)
Featured
|
AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK. |
|
| DC22001 |
AS-1269574
Featured
|
AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays. |
|
| DC22002 |
AS1928370 |
AS1928370 (ASP8370) is a potent, selective, orally available TRPV1 antagonist with IC50 of 0.51 uM, shows no inhibitory effects on TRPV4, TRPA11, and TRPM8 at 10 uM. |
|
| DC22766 |
AS-1949490 |
AS-1949490 (AS1949490) is a potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2. |
|
| DC20682 |
AS2521780 |
AS2521780 is a potent, selective, orally bioavailable PKCθ inhibitor that inhibits combinant human PKCθ enzyme with IC50 of 0.48 nM, >30-fold higher than other PKC isoforms. |
|
| DC3112 |
AS-252424
Featured
|
AS-252424 is a novel, potent and selective inhibitor of PI3Kγ with IC50 of 33 nM. |
|
| DC20683 |
AS2541019 |
AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM, >100-fold selectivity over other PI3K isoforms. |
|
| DC20684 |
AS2677131 |
AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM). |
|
| DC20035 |
AS2717638
Featured
|
AS2717638 is an oral active lysophosphatidic acid receptor 5 (LPA5) antagonist in rodents. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia. |
|
| DC7068 |
AS605240 |
AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα. |
|
| DC11407 |
Asapiprant(BGE-175)
Featured
|
Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit |
|
| DC20622 |
Asciminib
Featured
|
Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells. |
|
| DC4169 |
ASC-J9 |
ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors. |
|
| DC21100 |
Gusacitinib (ASN-002)
Featured
|
ASN-002 (Gusacitinib, ASN002) is a novel and potent dual inhibitor of SYK/JAK kinases with IC50 of 5-46 nM in biochemical assays. |
|
| DC20109 |
ASP-4058 |
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. |
|
| DC23457 |
ASP6432 |
ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM. |
|
| DC20693 |
ASP9436 |
ASP9436 (ASP-9436) is a potent, selective brain penetrant and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 8.0 nM, >420-fold selectivity over other PDE subtypes. |
|
| DC22003 |
Aspacytarabine |
Aspacytarabine (Astarabine, BST236) is a cytarabine conjugate that shows anti-neoplastic agents for inhibiting cancer cell growth. . |
|
| DC12360 |
Asp-AMS |
Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme. |
|
| DC7360 |
AST-1306 |
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
|
| DC11163 |
AST-3424
Featured
|
AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent. |
|
| DC20148 |
Astaxanthin |
Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is an inhibitor of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity. Astaxanthin has potential in the treatment of various di |
|
| DC23804 |
Astex ERK inhibitor X |
Astex ERK inhibitor X is a novel potent ERK1/2 inhibitor that inhibits ERK catalytic activity with IC50 of 3 nM in TRK kinase assays. |
|
| DC12617 |
Astin C |
Astin C is a cyclopeptide isolated from the medicinal plant Aster tataricus, inhibits cGAS-STING signaling and the innate inflammatory responses triggered by cytosolic DNAs, inhibits intracellular DNA-induced Ifnb expression with IC50 of 3.42 and 10.83 uM |
|
| DC12126 |
Astragaloside VI |
Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. |
|
